Thrombotic thrombocytopenic purpura resistant to plasma-exchange: Salvage treatment with high-dose IgG or vincristine

C. Porta, E. Bobbio-Pallavicini, R. Centurioni, F. Tacconi

Research output: Contribution to journalArticle

Abstract

Even though plasma-exchange (PE), either alone or combined with cortisone or platelet anti-aggregating substances is the treatment of choice for TTP, 10-15% of patients is resistant to treatment. Since immunoglobulin (IgG) infusion was reported to cure the clinical symptoms of PE-resistant TTP, and vincristine (VCR) has been recently successful in treating TTP, we reviewed the results obtained with both drugs in 20 PE-resistant patients. Of 12 patients receiving IgG and 8 receiving VCR, 3 (25%) and 4 (50%), respectively, achieved complete remission. Even though no conclusions can be drawn from such results, if complete remission can be achieved in a however small number of PE-resistant patients, the use of these drugs is suggested as a salvage treatment for TTP.

Original languageEnglish
Pages (from-to)201-204
Number of pages4
JournalInternational Journal of Artificial Organs
Volume16
Issue numberSUPPL. 5
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Biophysics

Fingerprint Dive into the research topics of 'Thrombotic thrombocytopenic purpura resistant to plasma-exchange: Salvage treatment with high-dose IgG or vincristine'. Together they form a unique fingerprint.

  • Cite this